switching from glp 1 to tirzepatide Early Dose Escalation of after Semaglutide in Type 2 Diabetes Mellitus Switching between GLP‐1 receptor agonists

This compound patent should technically expire in March 2026, which is twenty years from when the patent was filed

doi: 10.1056/NEJMoa2022190 51 FilippatosTDLiontosAPapakitsouIElisafMS

Surgical Forum 12:29496.[PubMed] , [Google Scholar])

Clinical studies show that users on GLP-1 weight loss programs may lose around 15%25% of their body weight over one year when combined with diet, exercise, and consistent support

Eligibility varies and often excludes people without commercial insurance or those enrolled in government plans

Victoza works by helping the body make more insulin (to help lower blood sugar levels) and less glucagon (because glucagon increases blood sugar)